The monoclonal antibody 9 (also known as YB2/90-5-20) reacts with a neoantigen on iC3, iC3b, C3dg and C3g. C3g itself however is a small fragment probably not formed in vivo. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components.

The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. An inherited deficiency of C3 predisposes the person to frequent bacterial infections. C3 fragments are deposited in tissues at sites of antibody-mediated immunopathology. In ulcerative colitis and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported.

Proteolysis by C3-convertases results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b and C3f. iC3b is further processed into C3c and C3dg. C3dg can be cleaved into C3d and C3g though this does not occur in plasma.

The monoclonal antibody 9 recognizes iC3b, C3dg and C3g in plasma. The monoclonal antibody does not recognize C3 or C3b.

### Description

**Catalog nr**

HM2199 (lot number and expiry date are indicated on the label)

**Formulation**

1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.02% sodium azide and 0.1% bovine serum albumin.

**Application**

The monoclonal antibody 9 can be used for immunoassays and for immunoprecipitation.

**Storage and stability**

Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.

**Precautions**

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.

### References

1. Lachmann, P et al; Three monoclonal antibodies to human C3. Immunology 1980, 41: 503
3. Lachmann, P et al; Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes. Vox Sang 1983, 45: 367
5. Mollnes, T et al; Activation of the third component of complement (C3) detected by a monoclonal anti-C3’g’ neoantigen antibody in a one-step enzyme immunoassay. J Immunol Methods 1987, 101: 201

### Also available

- HM2072: Monoclonal antibody against Human C3/C3b, clone 755
- HM2073: Monoclonal antibody against Human C3/C3a, clone 474
- HM2074: Monoclonal antibody against Human C3a/C3a des-Arg (neo-epitope), clone 2991
- HM2075: Monoclonal antibody against Human C3/C3a (C-terminus), clone 2898
- HM2168: Monoclonal antibody against Human activated C3, clone bH6
- HM2198: Monoclonal antibody against Human C3d, clone 3